Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAura Renew Acq Regulatory News (ARA)

Share Price Information for Aura Renew Acq (ARA)

Share Price is delayed by 15 minutes
Get Live Data
2.50    0.00 (0.00%)
Bid:
1.50
Ask:
3.50
Spread: 2.00 (133.333%)
Market Cap: £262.50k
ARA Live PriceLast checked at - London Stock Exchange

Intraday Aura Renew Acq Share Chart

Additional Listing

3 May 2006 15:26

Ardana PLC03 May 2006 3 May 2006 BLOCK LISTING Edinburgh, UK, 03 May 2006; Ardana plc (LSE:ARA) the emerging pharmaceuticalcompany focused on improving human reproductive health, today announces thatapplication has been made to the UK Listing Authority and the London StockExchange for a block listing of 2,494,967 ordinary shares of 1 (one) pence each. The application is in respect of shares to be allotted pursuant to theexercise of options under the Ardana Bioscience Employees' share option scheme,Ardana Ltd Employees' share option scheme and certain individual optionagreements between Ardana plc and non-executive directors and non-employees. For more information contact: ArdanaMaureen Lindsay Tel: + 44 (0) 131 226 8550 About Ardana Ardana plc is a pharmaceutical company focused on the discovery, development andmarketing of innovative products to improve human reproductive health, a $23.8billion market. Since its foundation, Ardana has maintained a broad and balanced portfolio tomanage risk and actively pursues product and technology in-licensing andout-licensing to maintain a robust pipeline. Ardana's four lead products are summarised below: â€Ē StriantTM SR, a testosterone replacement therapy for which Ardana has marketing rights in Europe, has already been launched by Ardana through its own sales force in the UK as a treatment for men with confirmed hypogonadism â€Ē Teverelix LA, in development for three initial indications: prostate cancer and benign prostatic hyperplasia (both indications are at the phase II stage), and endometriosis (currently in phase I) â€Ē Testo Cream, a transdermal testosterone delivery system in phase II for the treatment of male hypogonadism â€Ē Invicorp(R), an injectable combination drug treatment for erectile dysfunction, already approved in Denmark and for which Ardana has marketing and manufacturing rights in Europe. Launch is expected in H2 2006 In addition, Ardana has a strong portfolio of follow-on products in development.Ardana completed its IPO on the London Stock Exchange in March 2005 raisingÂĢ21 million. For further information please see www.ardana.co.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
26th May 20057:01 amRNSResearch Update
12th May 20057:00 amRNSResearch Update
19th Apr 20057:01 amRNSResearch Update
16th Mar 20053:50 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.